CMB International: Initiate coverage on Wuxi Biologics (02268.HK) with a "buy" rating and a target price of HK$74.

According to the China Fortune Finance App, Citi International has issued a research report covering WuXi AppTec (02268.HK) for the first time, giving it a "buy" rating with a target price of HK$74. The bank predicts that the company's revenue will increase by 45.7%, 35.7%, and 30.9% year-on-year from 2025 to 2027, while adjusted net profit will increase by 40%, 32.4%, and 30.8% year-on-year.